Headquartered in Ponte Vedra, FL Fiscal year ends December NASDAQ: TMCI treace.com
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) is a medical technology company focused on the surgical treatment of bunions and other foot and ankle conditions. Bunions are complex 3-dimensional deformities originating from an unstable midfoot joint. The company says they affect about 67 million Americans, of whom it estimates 1.1 million are annual surgical candidates.
Its core product is the patented Lapiplasty 3D Bunion Correction System, a combination of instruments, implants and surgical methods that corrects all three planes of the deformity and secures the unstable joint. The portfolio also includes:
- the Adductoplasty Midfoot Correction System;
- two minimally invasive osteotomy systems, Nanoplasty and Percuplasty;
- the SpeedMTP MTP Fusion System;
- the SpeedPlate rapid compression implant platform;
- IntelliGuide patient-specific pre-op planning and cut guide technology;
- SuperBite fully-threaded compression screws for fusions throughout the foot.
The company sells to foot and ankle surgeons, including through stocking distributors. Recent results reflect a mix shift toward lower-priced minimally invasive products, rising procedure volumes and cost reduction initiatives. The company is also pursuing patent infringement and unfair competition litigation against competitors. Updated
Treace hit positive adjusted EBITDA of $309,000, a year after a $2.6 million loss, by cutting operating expenses 10%. Management narrowed full-year revenue guidance to $206 million to $210 million and halved its expected adjusted EBITDA loss, putting the profitability turn within reach for a $272 million company.
With the earnings season winding down and windows for making insider purchases opening up, CEOs and other insiders have been scooping up shares.
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) is a medical technology company focused on the surgical treatment of bunions and other foot and ankle conditions. Bunions are complex 3-dimensional deformities originating from an unstable midfoot joint.
The Wall Street consensus 12-month price target for TMCI is $6.17.
